Close

News

Astellas Announces Construction of New Manufacturing Facility for Active Pharmaceutical Ingredient of Prograf

The new manufacturing facility is designed to have advanced features based on the efficiency of the existing facilities and requires approximately JPY10bn ($90m) in construction costs Japanese pharmaceutical firm Astellas has unveiled plans to construct the Third Fermentation Building as...

PharmaLex strengthens Healthcare Compliance services

PharmaLex Group, one of the most experienced and most successful specialist providers of Development Consulting, Regulatory Affairs, Pharmacovigilance, Epidemiology & Risk Management, and Quality Management & Compliance worldwide, have completed the merger with CompliMed in the United Kingdom. CompliMed is...

Focusing on Cutting-edge Biopharmaceutical Technologies, Boosting the Industry to Achieve Innovation and Development

To seize the ever-changing opportunities in the new era and to meet the ever-growing market demands, the annual gala of the biopharmaceutical industry--- bioLIVE China 2020, will be held again at Hall W4 in the SNIEC on June 22-24,...

Patient-Data Platform Raremark Enhances Executive Team to Accelerate Progress in Rare Disease Research

Raremark, the leading patient-data platform in rare disease, is pleased to announce additions to its executive team to speed the company’s pursuit of more treatments for rare medical conditions. Industry experts Neil Rotherham, Tim Davis and Jeremy Edwards have been...

Eli Lilly and Company in Collaboration with Strateos Launch Remote-Controlled Robotic Cloud Lab

Eli Lilly and Company and Strateos, Inc. unveiled a new robotic laboratory in San Diego, California designed to accelerate the drug discovery process. The Lilly Life Sciences Studio lab was conceptualized and designed by Lilly as part of a...

Moderna Announces Additional Positive Phase 1 Data from CMV Vaccine and First Participant Dosed in Phase 2 Study

Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced positive seven-month interim safety and immunogenicity data after the third and final vaccination in...

Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases

Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases. The new partnership combines Boehringer...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »